Niox Mino

Control airway inflammation, control asthma

While allergic airway inflammation is known to be the major underlying cause of asthma, there are few methods of measuring it. Evaluating airway inflammation using induced sputum or airway biopsy is expensive, invasive, time consuming, and often not readily available.

Now, there's NIOX MINO®— a device designed to measure airway inflammation at the point of care.

Patients with allergic airway inflammation generally have higher than normal levels of nitric oxide (NO) in their exhaled breath.1 By measuring the concentration of NO in an exhaled breath (fractional exhaled nitric oxide or FeNO), clinicians can evaluate allergic airway inflammation in patients with underlying asthma.

NIOX MINO® offers

Reasons to obtain a FeNO measurement

Assist in diagnosis1

  • Diagnose eosinophilic airway inflammation
  • Support the diagnosis of asthma when objective evidence is lacking
  • Help determine when respiratory symptoms are not due to asthma
  • Determine whether uncontrolled allergic airway inflammation is contributing to poor asthma control

Aid in treatment

  • Determine the likelihood of steroid responsiveness1
  • Guide stepwise changes in anti-inflammatory medication (step-down dosing, step-up dosing, or discontinuation)1

Assist in monitoring control and adherence1

  • Establish baseline FeNO level during a period of clinical stability, which can be subsequently monitored
  • Help determine whether patients are adhering to prescribed corticosteroid treatment

References: 1. Dweik RA, Boggs PB, Erzurum SC, et al; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615. 2. National Asthma Education and Prevention Program; National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Published August 28, 2007. Accessed September 13, 2011. 3. Pakhale S, Sumner A, Coyle D et al. (Correcting) misdiagnosis of asthma: a cost effectiveness analysis. BMMC Pulmonary medicine. 2011;11:27.

Congresses 2014

Don’t miss the Aerocrine “Improving Asthma Management” symposium with leading experts speaking about the hottest FeNO topics.

             ERS Annual Congress 2014

 

It has been estimated that the total lifetime medical cost for asthma medications in misdiagnosed patients amounted to over € 3000 per patient. Europe total 58 billion3

 

NIOX VERO®

Confirm
No
Yes
Confirm
No
Yes